Safety and Effectiveness of Cilostazol for Treating Adults with Nonalcoholic Fatty Liver Disease

What this Trial Is About

Nonalcoholic fatty liver disease NAFLD is a common chronic liver condition characterized by excess fat buildup in the liver not caused by alcohol or other known factors. This condition is a major health concern worldwide, especially in developed countries. The study aims to evaluate the safety and effectiveness of cilostazol, a drug that may improve liver fat, in adults diagnosed with NAFLD. Participants will be randomly assigned to one of two groups. One group will receive standard therapy, which includes regular exercise and calorie restriction, along with a placebo for three months. The other group will receive the same standard therapy plus cilostazol at a dose of 100 mg twice daily. The study will last for three months to assess the effects of these treatments. During the study, researchers will monitor changes in liver fat levels using ultrasound and assess fibrosis risk scores. Participants will follow prescribed exercise routines and dietary plans. Safety and treatment effects will be closely observed throughout the study period, which lasts three months. This trial is sponsored by Tanta University and includes adults aged 18 to 60 years with diagnosed fatty liver disease.

Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease